Validation experiment designed to validate causal mechanisms targeting NLRP3,APOE in ApoE-/- mice. Primary outcome: atherosclerotic plaque size and inflammatory markers
This experiment investigated the therapeutic effects of Resibufogenin (RBG) on atherosclerosis progression in ApoE-/- mice, a well-established model for studying atherosclerosis. The study assessed RBG's ability to reduce atherosclerotic plaque formation, improve lipid profiles, and modulate inflammatory responses. Mice were treated with RBG and various parameters were measured including body weight, atherosclerotic plaque size, serum lipid profiles, and inflammatory marker expression. The experiment demonstrated that RBG treatment effectively alleviated atherosclerosis symptoms by reducing plaque formation and improving metabolic parameters.
ApoE-/- mice were treated with RBG, followed by assessment of body weight, atherosclerotic plaque formation, serum lipid profiles, and inflammatory marker expression through transcriptomics and molecular biology techniques
RBG treatment was expected to reduce atherosclerotic plaque formation and inflammatory responses. Results showed reduced body weight, smaller atherosclerotic plaques, improved serum lipid profiles, and suppressed expression of inflammatory markers including NLRP3
reduction in plaque size, improved lipid profiles, decreased inflammatory markers
No debates yet
No results recorded yet. Use POST /api/experiments/{id}/results to record a result.